Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39450 HARMONY BIOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or ...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Luis Sanay - Head, IR John Jacobs - President and CEO Jeffrey Dierks - Chief Commercial Officer Jeffrey Dayno - Chief Medical Officer Sandip Kapadia - CFO Conference Call Participants Chris Howerton - Jefferies Danielle Brill - Raymond James Charles Duncan - Cantor Fitzgerald Graig Suvannavejh - Goldman Sachs Corinne Jenkins - Goldman Sachs David Amsellem - Piper Sandler Francois ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39450 HARMONY BIOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or othe ...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Luis Sanay - Head, IR John C. Jacobs - President and CEO Jeffrey Dierks - Chief Commercial Officer Jeffrey M. Dayno - Chief Medical Officer Sandip Kapadia - CFO Conference Call Participants Danielle Brill - Raymond James Chris Howerton - Jefferies Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler Corinne Jenkins - Goldman Sachs Francois Brisebois - Oppenheimer Operato ...

Harmony Biosciences Q1 2022 Financial and Business Update May 3, 2022 Legal Disclaimer This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be consi ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39450 HARMONY BIOSCIENCES HOLDINGS, INC. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR (Exact name of registrant as specified in its charter) (State or oth ...

Harmony Biosciences Company Overview April 2022 Legal Disclaimer This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be considered forward-looking ...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2021 Earnings Conference Call February 28, 2022 8:30 AM ET Company Participants Patti Bank - Investor Relations John Jacobs - President and Chief Executive Officer Jeffrey Dierks - Chief Commercial Officer Jeffrey Dayno - Chief Medical Officer Sandip Kapadia - Chief Financial Officer Conference Call Participants Danielle Brill - Raymond James Chris Howerton - Jefferies Ami Fadia - Needham David Amsellem - Piper Sandler Corinne Jenkins - Goldman Sachs Franç ...

HAR Harmony Biosciences Q4 2021 Financial and Business Update February 28, 2022 Legal Disclaimer This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, shoul ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39450 HARMONY BIOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in its charter) 630 W. Germant ...